Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.

Abstract:

:The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and JAK2 V617F presence. The revised IPSET-thrombosis uses three adverse variables to delineate four risk categories: age greater than 60, thrombosis history, and JAK2 V617F presence. We compared different risk models in the estimation of thrombotic risk in 191 patients with ET and the role of specific driver mutations affecting overall survival, according to thrombotic risk. We also evaluated the mutational status of patients showing history of thrombosis or cardiovascular events versus patients who did not. Finally, we verified whether the thrombotic risk had a significant impact on survival in our ET patients. The data analysis has been performed through the conventional statistics and overall survival estimated by using the Kaplan-Meyer method. Interestingly, either using the traditional system for thrombotic risk or the IPSET-t prognostic score or the current stratification for the thrombotic risk, high-risk patients are always highly represented. This evidence is of note, being the high-risk category indicated for cytoreduction, affecting quality of life, despite the good overall prognosis of patients with ET diagnosis in general. The analysis of overall survival in our patients, according to different models for thrombotic risk, highlighted the poor prognosis of high-risk patients compared with those with a lower thrombotic risk, in particular when using traditional stratification and current stratification. In conclusion, the occurrence of thrombotic or cardiovascular events represents one of the most severe complications at diagnosis or during follow-up of ET despite current recommendations, having a significant impact on morbidity and survival.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Santoro M,Accurso V,Mancuso S,Carlisi M,Raso S,Tarantino G,Di Piazza F,Perez A,Russo A,Siragusa S

doi

10.1002/hon.2670

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

434-437

issue

4

eissn

0278-0232

issn

1099-1069

journal_volume

37

pub_type

杂志文章
  • Research progress on exosomes derived from mesenchymal stem cells in hematological malignancies.

    abstract::Mesenchymal stem cells (MSCs) are a subset of multifunctional stem cells with self-renewal and multidirectional differentiation properties that play a pivotal role in tumor progression. MSCs are reported to exert biological functions by secreting specialized vesicles, known as exosomes, with tumor cells. Exosomes part...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2793

    authors: Lyu T,Zhang B,Li M,Jiao X,Song Y

    更新日期:2020-08-27 00:00:00

  • Is the Hodgkin cell a T- or B-lymphocyte? Recent evidence from geno- and immunophenotypic analysis and in-vitro cell lines.

    abstract::The cellular derivation of Hodgkin (H) and Reed-Sternberg (RS) cells remains a controversial issue. A large body of conflicting results in the literature led to a variety of discordant speculations. The application of immunophenotyping, molecular biology and tissue culture provided additional means for investigations ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2900070202

    authors: Drexler HG,Jones DB,Diehl V,Minowada J

    更新日期:1989-03-01 00:00:00

  • Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).

    abstract::Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080205

    authors: Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

    更新日期:1990-03-01 00:00:00

  • Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.

    abstract::In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2652

    authors: Della Starza I,Cavalli M,De Novi LA,Genuardi E,Mantoan B,Drandi D,Barbero D,Ciabatti E,Grassi S,Gazzola A,Mannu C,Agostinelli C,Piccaluga PP,Bomben R,Degan M,Gattei V,Guarini A,Foà R,Galimberti S,Ladetto M,Ferrero

    更新日期:2019-10-01 00:00:00

  • Retrovirus-associated adult T-cell leukemia-lymphoma: an epidemiologic study of five cases among Hawaii-born offspring of migrant Japanese.

    abstract::Adult T-cell leukemia-lymphoma (ATLL) is a distinct clinicopathologic entity etiologically linked to HTLV-I infection. We have identified five cases of retrovirus-associated ATLL among Hawaii-born first generation offspring (nisei) of migrant Japanese. Four patients were offspring of migrant Japanese (issei) who emigr...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070210

    authors: Yanagihara ET,Nakamura J,Kimura L,Oishi N

    更新日期:1989-03-01 00:00:00

  • Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level.

    abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120104

    authors: Parker D,Alison DL,Barnard DL,Child JA,Dovey G,Farish J,Norfolk DR,O'Brien CJ,Parapia LA,Sharp J

    更新日期:1994-01-01 00:00:00

  • Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.

    abstract::In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199912)17:4<149::aid-hon64

    authors: Liu A,Takahashi M,Toba K,Zheng Z,Hashimoto S,Nikkuni K,Furukawa T,Koike T,Aizawa Y

    更新日期:1999-12-01 00:00:00

  • Residual mediastinal widening following therapy in Hodgkin's disease.

    abstract::The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080303

    authors: Orlandi E,Lazzarino M,Brusamolino E,Caldera D,Morra E,Dore R,Di Giulio G,Bernasconi C

    更新日期:1990-05-01 00:00:00

  • Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9.

    abstract::The expression of two membrane antigens identified by the monoclonal antibodies (McAb) My9 and 3C5 has been investigated in cells from 80 acute leukemias. My9 was positive in the blasts of 33 out of the 38 (87 per cent) cases of acute myeloid leukemia (AML) tested, regardless of FAB subtype, and in 13 of 18 (72 per ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030306

    authors: Matutes E,Rodriguez B,Polli N,Tavares de Castro J,Parreira A,Andrews C,Griffin JD,Tindle RW,Catovsky D

    更新日期:1985-07-01 00:00:00

  • Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.

    abstract::Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1017

    authors: Gu K,Weisenburger DD,Fu K,Chan WC,Greiner TC,Aoun P,Smith LM,Bast M,Liu Z,Bociek RG,Bierman PJ,Armitage JO,Vose JM

    更新日期:2012-09-01 00:00:00

  • Auer rods in the acute myeloid leukemias: frequency and methods of demonstration.

    abstract::One hundred and twenty-five cases of acute myeloid leukemia (AML) were reviewed for the presence of Auer rods by two peroxidase methods. The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 20.8% but three times higher by peroxidase staining techniques using either benzidine base as a substrate (P...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900050306

    authors: Jain NC,Cox C,Bennett JM

    更新日期:1987-07-01 00:00:00

  • Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation.

    abstract::Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2195

    authors: Gupta A,Punatar S,Gawande J,Bagal B,Mathew L,Bhat V,Kannan S,Khattry N

    更新日期:2016-09-01 00:00:00

  • Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.

    abstract::Continuous administration of amphotericin B deoxycholate over 24 hours (24 h-D-AmB) is better tolerated than rapid infusions. However, toxicity and outcome have not been assessed in a homogenous patient population with acute myeloid leukaemia (AML). We retrospectively analysed renal function and outcome in all adult p...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2500

    authors: Rothenbühler C,Held U,Manz MG,Schanz U,Gerber B

    更新日期:2018-04-01 00:00:00

  • Low-dose radiotherapy in diffuse large B-cell lymphoma.

    abstract::Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2368

    authors: Furlan C,Canzonieri V,Spina M,Michieli M,Ermacora A,Maestro R,Piccinin S,Bomben R,Dal Bo M,Trovo M,Gattei V,Tirelli U,Franchin G,Bulian P

    更新日期:2017-12-01 00:00:00

  • A risk factor for relapse in Hodgkin's disease: female gender?

    abstract::A retrospective study of 163 patients with Hodgkin's disease treated between 1969 and 1987 was performed to identify adverse prognostic factors. One hundred and thirty-five patients (83 per cent) attained a complete remission and 42 (31 per cent) of these have relapsed (median follow-up--43 months). Using multivariate...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070503

    authors: Jeffery GM,Colls BM,Robinson BA,Fitzharris BM,Atkinson CH

    更新日期:1989-09-01 00:00:00

  • Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.

    abstract::Bone marrow (BM) trephine biopsy is a part of routine staging of patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The significance of lymphoid monoclonal population on flow cytometry (FC) of the BM aspirate in the presence of negative BM histology has not been clarified. In this study, we assessed ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2127

    authors: Wolach O,Fraser A,Luchiansky M,Shapiro C,Radnay J,Shpilberg O,Lishner M,Lahav M

    更新日期:2015-03-01 00:00:00

  • A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.

    abstract::Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/hon.2141

    authors: Ataei S,Hadjibabaie M,Moslehi A,Taghizadeh-Ghehi M,Ashouri A,Amini E,Gholami K,Hayatshahi A,Vaezi M,Ghavamzadeh A

    更新日期:2015-06-01 00:00:00

  • Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow.

    abstract::Composite plasma cell neoplasm (PCN) and low grade B-cell lymphoma (B-NHL) in the bone marrow are uncommon and raise the differential diagnosis of B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology. This can be a challenging differential diagnosis, and the distinctions are important becau...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2129

    authors: Hussein S,Gill K,Baer LN,Hoehn D,Mansukhani M,Jobanputra V,Bhagat G,Alobeid B

    更新日期:2015-03-01 00:00:00

  • BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.

    abstract::Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2344

    authors: Zeng K,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Z,Guo S,Yan Q,Guo Y

    更新日期:2017-12-01 00:00:00

  • Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.

    abstract::Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2647

    authors: Kiesewetter B,Lamm W,Neuper O,Mayerhoefer ME,Simonitsch-Klupp I,Raderer M

    更新日期:2019-10-01 00:00:00

  • Evidence of colony suppressor activity and deficiency of hematopoietic growth factors in hairy cell leukemia.

    abstract::The cause of myelosuppression in hairy cell leukemia (HCL) has been ascribed to a reduction of the circulating progenitor cell (CPC) compartment and to suppression of hematopoiesis by TNF-alpha. The present study was performed to evaluate the inhibitory effect of hairy cells (HCs) and a possible lack of hematopoietic ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900110207

    authors: Gasché C,Reinisch W,Schwarzmeier JD

    更新日期:1993-03-01 00:00:00

  • Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

    abstract::There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2635

    authors: Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

    更新日期:2019-08-01 00:00:00

  • A monoclonal antibody 1A6 to T-cell recognizes a common antigen expressed on lymphocytes from normal and leukemic patients, and inhibits NK cell activity.

    abstract::A new monoclonal antibody (MAB), IA61gG2a, has been derived from Balb/c mice after immunization with T-cell chronic lymphocytic leukemia (T-CLL). This monoclonal antibody, 1A6 was tested on normal human peripheral blood cells, leukemia patients' cells and leukemia-lymphoma cell lines. The results demonstrated that thi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070306

    authors: Togashi H,Ghoneum M,Takasugi M,Kasai K,Mugishima H,Billing R,Terasaki PI

    更新日期:1989-05-01 00:00:00

  • Protein kinase C isozyme expression in human leukemia-lymphoma cell lines--an immunocytochemical study.

    abstract::There have been an increasing number of reports describing a pivotal role for phosphorylation in cellular responses for cell differentiation and proliferation. We examined an immunocytochemical expression of protein kinase C(PKC) isozymes (type I, II, and III) in 22 leukemia-lymphoma cell lines. Of these cell lines, 2...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100602

    authors: Hojo H,Morimura Y,Abe M,Tominaga K,Nozawa Y,Nakamura N,Ono N,Tasaki K,Yamaguchi Y,Suzuki S

    更新日期:1992-11-01 00:00:00

  • Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.

    abstract::Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/hon.2750

    authors: Le Bris Y,Magrangeas F,Moreau A,Chiron D,Guérin-Charbonnel C,Theisen O,Pichon O,Canioni D,Burroni B,Maisonneuve H,Thieblemont C,Oberic L,Gyan E,Pellat-Deceunynck C,Hermine O,Delfau-Larue MH,Tessoulin B,Béné MC,Minviel

    更新日期:2020-10-01 00:00:00

  • A pilot study of ChlOPhEPP-B--a weekly regimen for patients with untreated advanced or recurrent Hodgkin's disease.

    abstract::Twenty-five patients with either previously untreated advanced Hodgkin's disease (HD) or with relapsed disease were treated with an intensive weekly chemotherapy regimen (ChlOPhEPP-B) in which the myelosuppressive combinations of epirubicin and chlorambucil, and procarbazine and etoposide alternated at two-week interv...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2900100604

    authors: Smith GM,Wright D,Child JA,Simmons AV,Norfolk DR,Barnard DL,Parker D,Parapia L

    更新日期:1992-11-01 00:00:00

  • Long-term results of treatment of patients with follicular lymphomas.

    abstract::The management of patients with follicular lymphoma is controversial, particularly in those with follicular small cleaved cell (FSCC) or nodular poorly differentiated lymphoma (NPDL). Some advocate no treatment until symptoms arise, while others prefer to treat with intensive combination regimens and others with singl...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900050207

    authors: Kalter S,Holmes L,Cabanillas F

    更新日期:1987-04-01 00:00:00

  • Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.

    abstract::Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析

    doi:10.1002/hon.2173

    authors: Sekine L,Morais VD,Lima KM,Onsten TG,Ziegelmann PK,Ribeiro RA

    更新日期:2015-12-01 00:00:00

  • A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT

    abstract::The goal of current management of patients with chronic phase chronic myeloid leukemia (CML) is to reach treatment-free remission with sustained deep molecular remission (DMR) being the prerequisite therefor. Second-generation tyrosine kinase inhibitors can induce deeper and faster remission than imatinib, but are oft...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2786

    authors: Heibl S,Buxhofer-Ausch V,Schmidt S,Webersinke G,Lion T,Piringer G,Kuehr T,Wolf D,Melchardt T,Greil R,Thaler J

    更新日期:2020-12-01 00:00:00

  • Malignant lymphomas of follicular centre cell origin in man. VII. Prognostic features in small cleaved cell lymphoma.

    abstract::To extend the clinical-pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage II...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070506

    authors: Stein RS,Greer JP,Cousar JB,Hendey GW,Wehner JH,Flexner JM,Collins RD

    更新日期:1989-09-01 00:00:00